Home > Oncology > ESMO 2021 > Lung Cancer > Adjuvant atezolizumab lowers relapse rate in resected NSCLC

Adjuvant atezolizumab lowers relapse rate in resected NSCLC

Presented By
Dr Enriqueta Felip, Vall d’Hebron Institute of Oncology, Spain
ESMO 2021
Phase 3, Impower010
An exploratory analysis from the Impower010 trial added support for the use of adjuvant immunotherapy post-chemotherapy for selected early-stage non-small cell lung cancer (NSCLC). Despite treatment with curative intent, up to 60% of patients with stage I-III NSCLC still experience disease relapse [1]. Impower010 (NCT02486718) is the first randomised phase 3 study to show significant disease-free survival (DFS) improvement with adjuvant cancer immunotherapy (atezolizumab) after adjuvant chemotherapy in patients with early-stage resected NSCLC [2]. Enrolled patients had completely resected stage IB-IIIA NSCLC and ECOG performance status 0–1. A total of 1,280 patients received up to four 21-day cycles of cisplatin-based chemotherapy (plus pemetrexed, docetaxel, gemcitabine, or vinorelbine). Next, 1,005 patients without progression after adjuvant chemotherapy w...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on